Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633594 · ClinicalTrials.gov registry record · Phase 1
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
A Phase 1 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT00633594 is a Phase 1 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 39 participants.
The verdict
NCT00633594, a Phase 1 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is a Phase I/II multicenter, open-label, dose-escalation study of rituximab, bortezomib, and lenalidomide in the first-line or second-line treatment of patients with Mantle Cell Lymphoma (MCL).
Interventions
- DRUG Rituximab
- DRUG Lenalidomide
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2008-06 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00633594
The ClinicalTrials.gov registry entry for NCT00633594 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rituximab is the first listed.
NCT00633594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00633594 about?
NCT00633594 is a clinical study titled "Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma". This is a Phase I/II multicenter, open-label, dose-escalation study of rituximab, bortezomib, and lenalidomide in the first-line or second-line treatment of patients with Mantle Cell Lymphoma (MCL).
What is the current status of trial NCT00633594?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2008-06. Estimated completion is 2016-11.
What interventions are being tested in trial NCT00633594?
The interventions under investigation include: Rituximab (DRUG), Lenalidomide (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00633594?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.